组织学消退与1-2期皮肤黑色素瘤良好预后相关
该队列研究分析荷兰和澳大利亚两个大型队列,纳入组织学证实的1-2期原发性侵袭性皮肤黑色素瘤患者,随访中位时间分别为4.5年和11.1年。多变量Cox分析显示,疾病消退与更好的无复发生存和总生存相关,尤其在薄至中等厚度肿瘤及浅表扩散型亚型中。
要点
- 组织学消退是1-2期黑色素瘤的有利预后因素
- 消退改善薄和中等厚度黑色素瘤的无复发生存
- 浅表扩散型亚型中消退改善无复发生存和总生存
核心结论
- 在荷兰和澳大利亚两个大型队列中,组织学消退是1-2期黑色素瘤患者的有利预后因素。
研究设计与样本
- 队列研究分析荷兰和澳大利亚两个大型成人队列,纳入2000-2014年治疗的组织学证实1-2期原发性侵袭性皮肤黑色素瘤患者,荷兰随访中位4.5年,澳大利亚11.1年。
- 荷兰患者使用PALGA病理登记和荷兰癌症登记数据,澳大利亚患者使用大型专科黑色素瘤治疗中心数据库。
主要发现
- 荷兰队列中,消退患者无复发生存HR为0.55(95% CI 0.48-0.63;P < .001),总生存HR为0.87(95% CI 0.79-0.96;P = .004)。
- 澳大利亚队列中,消退患者无复发生存HR为0.61(95% CI 0.52-0.72;P < .001),总生存HR为0.73(95% CI 0.64-0.84;P < .001)。
- 亚组分析显示,两个队列中消退改善薄和中等Breslow厚度黑色素瘤的无复发生存。
- 荷兰浅表扩散型患者中,消退的无复发生存HR为0.54(95% CI 0.46-0.63;P < .001),总生存HR为0.86(95% CI 0.76-0.96;P = .009);澳大利亚浅表扩散型患者中,无复发生存HR为0.67(95% CI 0.52-0.85;P = .001),总生存HR为0.72(95% CI 0.59-0.88;P = .001)。
临床怎么用
- 组织学消退可作为1-2期黑色素瘤预后评估的有利指标,尤其薄至中等厚度和浅表扩散型亚型。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Although regression is commonly observed in cutaneous melanoma, it is uncertain whether it is associated with patient prognosis. OBJECTIVE: To determine whether histologically confirmed regression was associated with better or worse survival in patients with primary cutaneous melanoma. DESIGN, SETTING, AND PARTICIPANTS: This cohort study analyzed data from 2 large cohorts of adults (one in the Netherlands and the other in Australia) with histologically proven, stage 1 and 2 primary, invasive cutaneous melanoma with known regression status treated between 2000 and 2014, with median follow-up times of 4.5 and 11.1 years for the Dutch and Australian cohorts, respectively. For the Dutch patients, population-based data from PALGA, the Dutch Pathology Registry, were used, and follow-up data were retrieved from the Netherlands Cancer Registry. For the Australian patients, data from the database of a large, specialized melanoma treatment center were used. MAIN OUTCOMES AND MEASURES: Multivariable Cox proportional hazards analyses were performed per cohort to assess recurrence-free survival (RFS) and overall survival (OS), and subgroup analyses according to Breslow thickness category and melanoma subtype were performed. RESULTS: A total of 17 271 Dutch patients and 4980 Australian patients were included. In both cohorts, survival outcomes were better for patients with disease regression. For Dutch patients, the hazard ratio (HR) for those with disease regression was 0.55 (95% CI, 0.48-0.63; P < .001) for RFS and 0.87 (95% CI, 0.79-0.96; P = .004) for OS; for the Australian patients, the HR was 0.61 (95% CI, 0.52-0.72; P < .001) for RFS and 0.73 (95% CI, 0.64-0.84; P < .001) for OS. Subgroup analyses showed that the presence of regression improved RFS within thin and intermediate Breslow thickness melanomas in both cohorts. For patients with superficial spreading melanoma (SSM) subtype, regression improved RFS and OS in both cohorts. For Dutch patients with SSM, the HR for those with disease regression was 0.54 (95% CI, 0.46-0.63; P < .001) for RFS and 0.86 (95% CI, 0.76-0.96; P = .009) for OS; for the Australian patients with SSM, the HR was 0.67 (95% CI, 0.52-0.85; P = .001) for RFS and 0.72 (95% CI, 0.59-0.88; P = .001) for OS. CONCLUSIONS AND RELEVANCE: In 2 large patient cohorts from 2 different continents, regression was a favorable prognostic factor for patients with stage 1 and 2 melanomas, especially in those with thin and intermediate thickness tumors and those with SSM subtype.
引用
- El Sharouni MA, Aivazian K, Witkamp AJ, et al. Association of Histologic Regression With a Favorable Outcome in Patients With Stage 1 and Stage 2 Cutaneous Melanoma. JAMA Dermatol. 2021. PMID: 33355600. doi:10.1001/jamadermatol.2020.5032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。